

AMENDMENT


Kindly amend the application, without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, as follows.

IN THE CLAIMS:

Kindly amend the claims, without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, to read as follows:

1-14. (Cancelled)

15. (Original) A vaccine composition against influenza virus in an equine host comprising at least one recombinant virus, selected from the group consisting of canarypox virus, fowlpox virus and pigeonpox virus, containing and expressing in the equine host at least one nucleic acid molecule encoding at least one heterologous influenza protein; and, as an adjuvant, a polymer having monomeric units of the formula:



in which R₁ and R₂ are identical or different and are H or CH₃; x is 0 or 1; y is 1 or 2; and x+y=2, or alternatively, as an adjuvant, a polymer of acrylic or methacrylic acid, wherein a single dose of the composition provides immunity against influenza virus.

16-20. (Cancelled)

21. (Original) The vaccine composition of claim 15 wherein the recombinant virus is a recombinant canarypox virus.

22-23. (Cancelled)

24. (Original) The vaccine composition of claim 15 wherein the equine influenza protein comprises equine influenza HA protein.

25. (Original) The vaccine composition of claim 24 wherein the recombinant virus is a canarypox virus.
26. (Original) The vaccine composition of claim 15 which comprises two or three recombinant canarypox viruses, each of which contains a nucleic acid molecule that encodes, and each of which expresses, an influenza HA protein from a different influenza strain.
27. (Original) The vaccine composition of claim 15 which comprises a recombinant canarypox virus that contains nucleic acid molecules that encode, and that expresses, two or three different influenza HA proteins, each of which is from a different strain of influenza virus.
28. (Original) The vaccine composition of claim 26 or 27, wherein at least one recombinant canarypox virus contains a nucleic acid molecule that encodes and expresses an influenza HA protein from Influenza A / equi-2 / Newmarket / 2 / 93.
29. (Cancelled)